For antibody development, in vitro screening and validation models play an irreplaceable role in accelerating the discovery and screening process of antibody candidates. The cell-based binding assay is one of the important experiment models, which provides convenience for early antibody screening and validation process.
Comparing other approaches, cell-based binding assay represents various advantages:
Leveraging our comprehensive range of detection methods and expertise in the antibody development fields, Creative Biolabs specializes in providing robust and efficient in vitro cell-based binding assays. We have established 100+ cell lines with high standards to support cell-based assays. Meanwhile, we provide several sensitive analysis services at the cellular level for antibody drug development, including the following items.
| Approaches | Readout | |
|
The target protein on the cell surface can bind to the test sample (such as antibody, ADC, etc.), and the specific fluorescence value can be detected through the fluorescent secondary antibody to reflect the binding ability of the test sample to the target protein of the cell surface. | Fluorescence |
|
In the blocking test, additional receptor ligands are added for binding with the antibody sample to be tested using FACS. And the specific fluorescence value can be detected through the fluorescent secondary antibody to reflect the blocking activity of the test samples. | |
|
In the competition test, additional Target Ab will be added to bind with the target protein. When antibody samples inhibit the binding of Target Ab to the target antigen, indicating that antibody samples can recognize the same epitope. | |
|
A direct immunochemical labeling step that combines cell culture and ELISA. | Absorbance |
Cell-based binding test can be regarded as the key step that is often used in drug screening and characterization. There are many application scenarios for cell-based binding tests:
Here are some representative data for cell-based binding assays.
Fig.1 Binding analysis of antibody candidates with OVCAR-3 cells by flow cytometry.
Fig.2 CAR expression evaluation in BCMA-CAR-T cells. CAR expressions were confirmed by flow cytometry with different reagents (BCMA antibody, anti-human IgG antibody, and BCMA peptide).1
Fig.3 Mammalian cell-based competition assay by flow cytometry.2
For more detailed information about our cell-based binding assay service, please feel free to contact us or directly send us an inquiry.
References
For Research Use Only.
